MyFinsight
Home
Blog
About
Cash and cash
equivalents
$28,712,000
(385.41%↑ Y/Y)
Prepaid expenses and
other current assets
$133,000
(-18.73%↓ Y/Y)
Total current assets
$28,845,000
(374.53%↑ Y/Y)
Equity method
investment
$241,000
(-66.53%↓ Y/Y)
Intangible assets, net
$3,000
(-2.15%↓ Y/Y)
Total assets
$29,089,000
(327.67%↑ Y/Y)
Accumulated deficit
-$143,984,000
(-67.07%↓ Y/Y)
Total liabilities,
temporary equity and...
$29,089,000
(327.67%↑ Y/Y)
Total stockholders
(deficit) equity
-$38,377,000
(-786.45%↓ Y/Y)
Additional paid in capital
$105,604,000
(15.10%↑ Y/Y)
Common stock,
100,000,000 shares...
$3,000
(-86.07%↓ Y/Y)
Series a convertible
preferred stock, 0.001 par...
$38,533,000
Total liabilities
$28,933,000
(2289.13%↑ Y/Y)
Milestone warrant rights
liability
$23,812,000
Total current
liabilities
$5,121,000
(322.86%↑ Y/Y)
Accounts payable
$2,624,000
(290.99%↑ Y/Y)
Accrued expenses
$2,497,000
(362.49%↑ Y/Y)
Back
Back
Balance Sheet
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)
source: myfinsight.com